BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37115038)

  • 1. Molecular and clinicopathologic characterization of pediatric histiocytoses.
    Hélias-Rodzewicz Z; Donadieu J; Terrones N; Barkaoui MA; Lambilliotte A; Moshous D; Thomas C; Azarnoush S; Pasquet M; Mansuy L; Aladjidi N; Jeziorski E; Marec-Berard P; Gilibert-Yvert M; Spiegel A; Saultier P; Pellier I; Pagnier A; Pertuisel S; Poiree M; Bodet D; Millot F; Isfan F; Stephan JL; Leruste A; Rigaud C; Filhon B; Carausu L; Reguerre Y; Kieffer I; Brichard B; Ben Jannet R; Bakari M; Idbaih A; Bodemer C; Cohen-Aubart F; Haroche J; Tazi A; Boudjemaa S; Fraitag S; Emile JF; Heritier S;
    Am J Hematol; 2023 Jul; 98(7):1058-1069. PubMed ID: 37115038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
    Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of
    Razanamahery J; Godot A; Leguy-Seguin V; Samson M; Audia S; Bonnotte B
    Front Immunol; 2023; 14():1260193. PubMed ID: 37809108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
    Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF
    Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
    Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
    Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
    Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
    Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K
    Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
    Allen CE; Parsons DW
    Hematology Am Soc Hematol Educ Program; 2015; 2015():559-64. PubMed ID: 26637772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
    Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
    Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
    J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
    Haroche J; Abla O
    Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
    Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
    Jouenne F; Chevret S; Bugnet E; Clappier E; Lorillon G; Meignin V; Sadoux A; Cohen S; Haziot A; How-Kit A; Kannengiesser C; Lebbé C; Gossot D; Mourah S; Tazi A
    Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31806714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma.
    Techavichit P; Sosothikul D; Chaichana T; Teerapakpinyo C; Thorner PS; Shuangshoti S
    Hum Pathol; 2017 Nov; 69():118-122. PubMed ID: 28504206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adult xanthogranuloma with a small portion of BRAF
    Ishikawa M; Endo Y; Uehara A; Suto M; Yasuda M; Motegi SI; Ishikawa O
    J Dermatol; 2019 Feb; 46(2):161-165. PubMed ID: 30536719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
    Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
    Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
    Abla O; Weitzman S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
    Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.